依折麦布联合他汀类药物对肾病作用的研究进展
被引量:6
摘要
高脂血症与肾脏疾病关系密切,它既是其常见的临床表现,又参与其发生和进展。血脂异常作为肾小球硬化发生和进展的独立危险因素可损伤血管内皮细胞,引起炎性反应,促进肾脏动脉粥样硬化发生,并对肾脏细胞具有直接毒性,加速慢性肾脏疾病(CKD)的进展。肾功能恶化又会加重高脂血症,
出处
《中国医师进修杂志》
2013年第25期73-75,共3页
Chinese Journal of Postgraduates of Medicine
基金
黑龙江省科技计划(QCOSC13)
二级参考文献10
-
1Raúl J Andrade,Mercedes Robles,Alejandra Fernández-Castaer,Susana López-Ortega,M Carmen López-Vega,M Isabel Lucena.Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists[J].World Journal of Gastroenterology,2007,13(3):329-340. 被引量:18
-
2Qiang Liu,Hillel Tobias,Lydia M. Petrovic.Drug-Induced Liver Injury Associated with Ezetimibe Therapy[J].Digestive Diseases and Sciences.2007(2)
-
3Jackevicius CA,Tu JV,Ross JS,Ko DT,Krumholz HM.Use of ezetimibe in the United States and Canada[].The New England Journal of Medicine.2008
-
4Bhardwaj SS,Chalasani N.Lipid-lowering agents that cause drug-induced hepatotoxicity[].Clinics in Liver Disease.2007
-
5Maddrey WC.Drug-induced hepatotoxicity: 2005[].Journal of Clinical Gastroenterology.2005
-
6Stolk MF,Becx MC,Kuypers KC,Seldenrijk CA.Severe hepatic side effects of ezetimibe[].Clinics in Gastroenterology.2006
-
7Liu Q,Tobias H,Petrovic LM.Drug-induced liver injury associated with ezetimibe therapy[].Digestive Diseases and Sciences.2007
-
8Sabate M,Ibanez L,Perez E,Vidal X,Buti M,Xiol X,Mas A,Guarner C,Forne M,Sola R,Castellote J,Rigau J,Laporte JR.Risk of acute liver injury associated with the use of drugs: a multicentre population survey[].Alimentary Pharmacology and Therapeutics.2007
-
9Fernando Civeira and International Panel on Management of Familial Hypercholesterolemia.Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia[].Atherosclerosis.2004
-
10van Heyningen C.Drug-induced acute autoimmune hepa-titis during combination therapy with atorvastatin and ezetimibe[].Annals of Clinical Biochemistry.2005
同被引文献54
-
1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5219
-
2Fatica RA, Dennis VW. Cardiovascular mortality in chronic renal failure., hyperphosphatemia, coronary calcification, and the role of phosphate binders[J]. Cleve Clin J IVied, 2002, 69 (Suppl 3) : S21-S27.
-
3Catapano AL, Reiner Z,DeBacker G, et al. ESC/EAS Guide- lines for the management of dyslipidaemias The TaskForce for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society (EAS)[J]. Atherosclerosis, 2011, 217(1): 3-46.
-
4Balaskas EV, Bamihas GI, Tourkantonis A. Management of lipid abnomalities in patients with CAPD[J]. Perit Dial Int, 1997, 17: 308-309.
-
5Little J, Phillips L,Russel L, et al. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factor[J]. J Am Soc Nephrol, 1998, 9(10): 1931- 1939.
-
6Daum U, Leren TP,Langer C, et al. Multiple dysfunctions of two apolip oprotein A-I (R160L) also and apoA-I (P165R), that are associated with hypoalphali poproteinemia in heterozy- gous carriers[J]. J Lipid Res, 1999, 40(3): 486-494.
-
7Delarve J, Maingourd C,Couet C, et al. Effect of oral glucose on intermediary metabolism in continuous ambulatory perito- neal dialysis patients versus healthy subjects[J3. Perit Dial Int, 1998, 18(5): 505-511.
-
8Goren A, Stankiewicz H,Goldstein R, et al. Fishoil treatment of hyper lipidemia in children and adolescents receiving renal replacement therapy[J]. Pediatrics, 1991, 88: 265-268.
-
9Cholesterol Treatment Trialists" Ctt Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841) ; 581- 590.
-
10Kones IL Primary prevention of coronary heart disease: inte- gration of new data, evol;Jing views, revised goals, and role of rosuvasatin in management[J]. Drug Des DeVel Ther, 2011, 5 : 325-380.
引证文献6
-
1贾维敏,张志.依折麦布联合辛伐他汀治疗2型糖尿病合并高脂血症的临床观察[J].中国医学创新,2014,11(25):65-67. 被引量:5
-
2陈文莉,徐力,毛辉辉,李永霞.依折麦布联合阿托伐他汀钙治疗腹膜透析患者高脂血症的观察[J].临床肾脏病杂志,2015,15(3):161-164. 被引量:7
-
3谭尧月,刘俊,李泽,王娟,史国兵,张德伟,党大胜.短期应用阿托伐他汀联合依折麦布对原发性肾病综合征合并高脂血症患者降脂疗效及相关指标的影响[J].中国药房,2017,28(6):773-776. 被引量:22
-
4戴文茜,宫凤云,李帆.依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的长期随访研究[J].医药论坛杂志,2017,38(1):27-29. 被引量:2
-
5刘书馨,金蕊,刘红,王志宏,滕兰波,董毳,郐婷婷,张瑜.糖尿病肾病与非糖尿病肾病维持性血液透析患者生存率比较的历史队列研究[J].中国医师进修杂志,2019,42(9):771-776. 被引量:32
-
6莫丽德尔.白山,班努.库肯,许长生,潘玲,严金龙.阿托伐他汀联合依折麦布与单用阿托伐他汀对ASCVD患者的有效性和安全性研究[J].世界最新医学信息文摘,2018,18(34):32-34. 被引量:1
二级引证文献67
-
1关翠嫦,谢晓宁.维持性血液透析患者生理、心理和社会问题的调查分析[J].慢性病学杂志,2020(8):1147-1150. 被引量:1
-
2杨丽群.肝病合并糖尿病肾病维持性血液透析患者的饮食护理[J].透析与人工器官,2021,32(1):90-92. 被引量:6
-
3付红英,程丽丽,谢梦琦.协同护理模式在糖尿病肾病血液透析患者中的应用价值[J].透析与人工器官,2021,32(1):48-50. 被引量:2
-
4肖岚.依折麦布与阿托伐他汀联用对冠心病高危患者血脂的影响[J].世界临床医学,2018,12(1):28-28. 被引量:1
-
5刘刚.GC1—3型送布牙及针距的调整(兼答江正标来信:NO:E—083)[J].中外缝制设备,2000(3):49-50.
-
6刘旭颖.伴高脂血症的阿尔茨海默病小鼠模型的构建[J].中国实用医药,2015,10(28):284-285. 被引量:1
-
7汤庆军.依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾的保护效果[J].医学临床研究,2016,33(4):686-689. 被引量:7
-
8李荣,郑义,肖艳平.阿托伐他汀钙联合依折麦布药物对冠心病治疗效果与临床安全性评价[J].心肺血管病杂志,2016,35(4):266-268. 被引量:63
-
9彭高伟,许国兵.依折麦布联合阿托伐他汀治疗2型糖尿病合并高脂血症的临床疗效[J].海峡药学,2017,29(7):85-87. 被引量:6
-
10陈艳芳.依折麦布联合阿托伐他汀治疗原发性高脂血症的探讨[J].海峡药学,2017,29(8):97-99. 被引量:2
-
1顾金林,顾同进,郑松柏.头孢他啶治疗老年人下呼吸道严重感染的再评价(附41例疗效分析)[J].老年医学与保健,1996,2(1):25-27. 被引量:1
-
2雷招宝.二肽基肽酶Ⅳ抑制剂与急性胰腺炎[J].药物不良反应杂志,2013,15(6):342-345.
-
3李慧妍,魏.血管紧张素转化酶抑制剂类药物致肾功能恶化3例报告[J].中国煤炭工业医学杂志,2003,6(6):565-565. 被引量:1
-
4杨立明,傅晓霞.乳酸左氧氟沙星治疗尿路感染的临床研究[J].中国抗生素杂志,2000(C00):28-28.
-
5刘进,盛丹.别嘌呤醇降低血尿酸水平以控制慢性肾病进展的研究[J].中国药房,2007,18(32):2524-2525. 被引量:4
-
6杨彩丽.低分子肝素钙治疗原发性肾病综合征临床观察[J].中国实用医药,2012,7(12):176-177. 被引量:10
-
7王逢春,何剑琴,杨铁城,田文洪,孙艳.促红细胞生成素治疗肾性贫血的疗效观察[J].中国药房,2005,16(14):1088-1090.
-
8向清,史伟,吴金玉,向彩春.贝那普利联合厄贝沙坦治疗糖尿病肾病疗效观察[J].中南药学,2008,6(4):490-493. 被引量:6
-
9杨明根,赵晓昆.α1受体阻滞剂治疗良性前列腺增生合并高血压研究进展[J].中华男科学杂志,2007,13(9):830-834. 被引量:18
-
10徐济民.改善血管内皮功能的降压药研究进展知识问答[J].社区卫生保健,2010(1):75-76.